Summary | |
---|---|
Symbol | IGF1R |
Name | insulin-like growth factor 1 receptor |
Aliases | JTK13; CD221; IGFIR; MGC18216; IGFR; IGF-I receptor; insulin-like growth factor I receptor; soluble IGF1R va ...... |
Chromosomal Location | 15q26.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane Single-pass type I membrane protein |
Domain |
PF00757 Furin-like cysteine rich region PF07714 Protein tyrosine kinase PF01030 Receptor L domain |
Function |
Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.; FUNCTION: When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin. |
Biological Process |
GO:0001933 negative regulation of protein phosphorylation GO:0006260 DNA replication GO:0006275 regulation of DNA replication GO:0006469 negative regulation of protein kinase activity GO:0007254 JNK cascade GO:0008286 insulin receptor signaling pathway GO:0014065 phosphatidylinositol 3-kinase signaling GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0030335 positive regulation of cell migration GO:0031098 stress-activated protein kinase signaling cascade GO:0032868 response to insulin GO:0032869 cellular response to insulin stimulus GO:0032872 regulation of stress-activated MAPK cascade GO:0033673 negative regulation of kinase activity GO:0038083 peptidyl-tyrosine autophosphorylation GO:0040017 positive regulation of locomotion GO:0042326 negative regulation of phosphorylation GO:0043405 regulation of MAP kinase activity GO:0043409 negative regulation of MAPK cascade GO:0043434 response to peptide hormone GO:0045740 positive regulation of DNA replication GO:0046328 regulation of JNK cascade GO:0046777 protein autophosphorylation GO:0048009 insulin-like growth factor receptor signaling pathway GO:0048015 phosphatidylinositol-mediated signaling GO:0048017 inositol lipid-mediated signaling GO:0051052 regulation of DNA metabolic process GO:0051054 positive regulation of DNA metabolic process GO:0051259 protein oligomerization GO:0051262 protein tetramerization GO:0051272 positive regulation of cellular component movement GO:0051348 negative regulation of transferase activity GO:0051389 inactivation of MAPKK activity GO:0051403 stress-activated MAPK cascade GO:0070302 regulation of stress-activated protein kinase signaling cascade GO:0071375 cellular response to peptide hormone stimulus GO:0071417 cellular response to organonitrogen compound GO:0071900 regulation of protein serine/threonine kinase activity GO:1901652 response to peptide GO:1901653 cellular response to peptide GO:1902532 negative regulation of intracellular signal transduction GO:2000147 positive regulation of cell motility |
Molecular Function |
GO:0004713 protein tyrosine kinase activity GO:0004714 transmembrane receptor protein tyrosine kinase activity GO:0005010 insulin-like growth factor-activated receptor activity GO:0005158 insulin receptor binding GO:0005520 insulin-like growth factor binding GO:0017046 peptide hormone binding GO:0019199 transmembrane receptor protein kinase activity GO:0019838 growth factor binding GO:0031994 insulin-like growth factor I binding GO:0033218 amide binding GO:0042277 peptide binding GO:0042562 hormone binding GO:0043548 phosphatidylinositol 3-kinase binding GO:0043559 insulin binding GO:0043560 insulin receptor substrate binding |
Cellular Component |
GO:0035867 alphav-beta3 integrin-IGF-1-IGF1R complex GO:0043235 receptor complex |
KEGG |
hsa04014 Ras signaling pathway hsa04015 Rap1 signaling pathway hsa04066 HIF-1 signaling pathway hsa04068 FoxO signaling pathway hsa04114 Oocyte meiosis hsa04140 Regulation of autophagy hsa04144 Endocytosis hsa04150 mTOR signaling pathway hsa04151 PI3K-Akt signaling pathway hsa04152 AMPK signaling pathway hsa04510 Focal adhesion hsa04520 Adherens junction hsa04550 Signaling pathways regulating pluripotency of stem cells hsa04730 Long-term depression hsa04913 Ovarian steroidogenesis hsa04914 Progesterone-mediated oocyte maturation |
Reactome |
R-HSA-2428924: IGF1R signaling cascade R-HSA-2428928: IRS-related events triggered by IGF1R R-HSA-2428933: SHC-related events triggered by IGF1R R-HSA-162582: Signal Transduction R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) |
Summary | |
---|---|
Symbol | IGF1R |
Name | insulin-like growth factor 1 receptor |
Aliases | JTK13; CD221; IGFIR; MGC18216; IGFR; IGF-I receptor; insulin-like growth factor I receptor; soluble IGF1R va ...... |
Chromosomal Location | 15q26.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between IGF1R and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between IGF1R and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | IGF1R |
Name | insulin-like growth factor 1 receptor |
Aliases | JTK13; CD221; IGFIR; MGC18216; IGFR; IGF-I receptor; insulin-like growth factor I receptor; soluble IGF1R va ...... |
Chromosomal Location | 15q26.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of IGF1R in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | IGF1R |
Name | insulin-like growth factor 1 receptor |
Aliases | JTK13; CD221; IGFIR; MGC18216; IGFR; IGF-I receptor; insulin-like growth factor I receptor; soluble IGF1R va ...... |
Chromosomal Location | 15q26.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of IGF1R in various data sets.
|
Points in the above scatter plot represent the mutation difference of IGF1R in various data sets.
|
Summary | |
---|---|
Symbol | IGF1R |
Name | insulin-like growth factor 1 receptor |
Aliases | JTK13; CD221; IGFIR; MGC18216; IGFR; IGF-I receptor; insulin-like growth factor I receptor; soluble IGF1R va ...... |
Chromosomal Location | 15q26.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IGF1R. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | IGF1R |
Name | insulin-like growth factor 1 receptor |
Aliases | JTK13; CD221; IGFIR; MGC18216; IGFR; IGF-I receptor; insulin-like growth factor I receptor; soluble IGF1R va ...... |
Chromosomal Location | 15q26.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IGF1R. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IGF1R. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | IGF1R |
Name | insulin-like growth factor 1 receptor |
Aliases | JTK13; CD221; IGFIR; MGC18216; IGFR; IGF-I receptor; insulin-like growth factor I receptor; soluble IGF1R va ...... |
Chromosomal Location | 15q26.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IGF1R. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | IGF1R |
Name | insulin-like growth factor 1 receptor |
Aliases | JTK13; CD221; IGFIR; MGC18216; IGFR; IGF-I receptor; insulin-like growth factor I receptor; soluble IGF1R va ...... |
Chromosomal Location | 15q26.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of IGF1R expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | IGF1R |
Name | insulin-like growth factor 1 receptor |
Aliases | JTK13; CD221; IGFIR; MGC18216; IGFR; IGF-I receptor; insulin-like growth factor I receptor; soluble IGF1R va ...... |
Chromosomal Location | 15q26.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between IGF1R and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | IGF1R |
Name | insulin-like growth factor 1 receptor |
Aliases | JTK13; CD221; IGFIR; MGC18216; IGFR; IGF-I receptor; insulin-like growth factor I receptor; soluble IGF1R va ...... |
Chromosomal Location | 15q26.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting IGF1R collected from DrugBank database. |
Details on drugs targeting IGF1R.
|